Mozart Therapeutics
14 known investors
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments. The company is founded on research from Stanford University scientists and is led by experienced biopharmaceutical industry executives.
Also known as Mozart Tx
Founders & leadership
Investors · 14
Also in the syndicate · 4
Funding
SEC filings, press & company announcements$25M disclosed across 1 of 2 rounds · 2023
- $25MSeries A extensionJun 2023 · 2 sources
AbbVie Ventures, Alexandria Venture Investments, Altitude Life Science Ventures, ARCH Venture Partners, Eli Lilly & Company, Leaps by Bayer, MRL Ventures Fund, Ono Venture Investment, Pfizer Ventures, Sofinnova Partners, UPMC Enterprises
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Aug 2026Mozart Therapeutics is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, developing first-in-class biologics that modulate regulatory CD8 T cells ("CD8 Treg") to treat autoimmune and inflammatory diseases. The company's thesis is that CD8 Treg are critical mediators of immune tolerance and immune homeostasis, and that their dysfunction allows the immune system to attack healthy "self" tissue; Mozart's therapies are designed to restore innate CD8 Treg function, suppress or eliminate pathogenic self-reactive CD4 T cells, and prevent downstream chronic inflammation and progressive tissue damage.
The lead program, MTX-101, is a bispecific antibody described as an autoimmune checkpoint inhibitor that targets CD8 and inhibitory KIR (KIR2DL) expressed on regulatory CD8 T cells, restoring their cytolytic function. MTX-101 entered a Phase 1a/b clinical study (NCT06324604) with first-cohort dosing announced in June 2024; the Phase 1a portion is a single and multiple ascending dose escalation study in healthy adults, and the Phase 1b portion is a prospective, multi-center, randomized, double-blind, placebo-controlled trial in patients with type 1 diabetes mellitus or celiac disease. A cytokine-based CD8 Treg network modulator, including a targeted IL-15 program, is in earlier-stage development. Company materials state its science builds on Nobel award-winning work and the research of Professor Mark Davis, who first described the network of immune cells responsible for maintaining immune tolerance and characterized CD8 Treg.
Business model
Biotechnology R&D company financed by venture and corporate strategic investors, developing proprietary protein/antibody therapeutics through clinical trials.
Traction
Completed a Phase 1a study in healthy adults showing MTX-101 was well tolerated and selectively activates CD8 Treg (March 2025); presented preclinical data on restoration of CD8 Treg functionality in type 1 diabetes and early data from its targeted IL-15 program at Immunology 2025 (May 2025); announced positive interim Phase 1 data in adults with Stage 3 type 1 diabetes (April 2026).
Latest developments
On April 23, 2026, Mozart announced positive interim Phase 1 data in adults with Stage 3 type I diabetes. Earlier, in May 2025, it presented preclinical data on CD8 Treg restoration in type 1 diabetes plus early data from its targeted IL-15 program, and in March 2025 it reported completion of the Phase 1a study showing MTX-101 was well tolerated and selectively activated CD8 Treg.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Positions itself as a leading developer of CD8 Treg network modulators, describing its programs as first-in-class and differentiated from broad immunosuppressive approaches.
Targets the regulatory CD8 T cell network rather than broadly suppressing the immune system; an investor (UPMC Enterprises) described the approach as novel and unique, with potential to modulate disease-driving immune pathways without the broad immunosuppression associated with existing therapies.
Technology
First-in-class biologics that modulate regulatory CD8 T cells. Lead asset MTX-101 is a bispecific antibody / autoimmune checkpoint inhibitor targeting CD8 and inhibitory KIR (KIR2DL) on CD8 Treg to restore their cytolytic function against pathogenic self-reactive CD4 T cells. A cytokine-based CD8 Treg network modulator and a targeted IL-15 program are also in the pipeline.
Go-to-market
Patients with autoimmune and inflammatory diseases, with initial clinical focus on type 1 diabetes mellitus and celiac disease, and autoimmune-mediated gastrointestinal disease.
Geography
Headquartered in Seattle, Washington, USA; Phase 1b trial described as multi-center.
History
The company raised a Series A that was extended by $25 million in June 2023, bringing the total raise to $80 million. It filed to enter the clinic with MTX-101, dosing the first cohort of a Phase 1a/b study in June 2024, completed the Phase 1a portion by March 2025, and reported positive interim Phase 1 data in Stage 3 type 1 diabetes in April 2026.
Risks & controversies
Programs remain in early clinical development (Phase 1), with efficacy in autoimmune indications not yet established; the sources report no controversies.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 4
by search overlap
Companies competing with Mozart Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 6
launches, deals, and filingsMozart announced positive interim Phase 1 data in adults with Stage 3 type I diabetes.
Mozart presented preclinical data showing restoration of CD8 Treg functionality in type 1 diabetes and early data from its targeted IL-15 program.
Mozart announced completion of its Phase 1a study, with data showing MTX-101 was well tolerated and selectively activates CD8 Treg.
Mozart dosed the first cohort of participants in its initial clinical study (NCT06324604) of MTX-101, a bispecific CD8 Treg modulator/autoimmune checkpoint inhibitor; Phase 1a evaluates safety, PK and PD in healthy adults and Phase 1b is a randomized, double-blind, placebo-controlled trial in patients with type 1 diabetes mellitus or celiac disease.
Mozart Therapeutics announced a $25 million Series A extension from new investors Pfizer Ventures, AbbVie Ventures, Ono Venture Investment and UPMC Enterprises, joining existing investors ARCH Venture Partners, Sofinnova Partners, Eli Lilly & Company, MRL Ventures Fund, Leaps by Bayer, Altitude Life Science Ventures and Alexandria Venture Investments. Total raise reached $80 million; proceeds fund MTX-101 clinical development and pipeline expansion.
$25M source ↗
In association with the Series A extension, Marie-Claire Peakman, PhD (Partner, Pfizer Ventures) and Jasmina Marjanovic, PhD (Director, AbbVie Ventures) joined Mozart's Board of Directors.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Mozart Therapeuticsmozart-tx.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Mozart Therapeutics do?
- Seattle-based clinical-stage biopharma developing CD8 Treg-modulating biologics for autoimmune and inflammatory diseases.
- Who founded Mozart Therapeutics?
- Mozart Therapeutics was founded by Mark Davis, K. Christopher Garcia, Calvin Kuo.
- Who are Mozart Therapeutics's investors?
- Mozart Therapeutics's investors include ARCH Venture Partners, JDRF T1D Fund, MRL Ventures Fund, Ono Venture Investment, Inc., Pfizer Venture Investments, Sofinnova Partners, Alexandria, ALTITUDE LIFE SCIENCE VENTURES and 2 more.
- How much funding has Mozart Therapeutics raised?
- Mozart Therapeutics has disclosed $25M raised across 1 of its 2 known rounds.